Growth factors as active participants in carcinogenesis: a perspective

Area of Science:

• Molecular Biology
• Oncology
• Pharmacology

Background:

• Growth factors are peptides crucial for cell proliferation, embryonic development, and differentiation.
• Cancer therapies increasingly target cell signaling pathways, including those involving growth factors.
• Targeting growth factor receptors with monoclonal antibodies or tyrosine kinase inhibitors is a key strategy in oncology.

Purpose of the Study:

• To review the role of growth factors in normal development and disease.
• To discuss therapeutic strategies targeting growth factor signaling in human malignancies.
• To explore the use of growth factors in managing chemotherapy side effects.

Main Methods:

• Review of scientific literature on growth factor biology and cancer therapy.
• Analysis of therapeutic modalities involving growth factor activity or inhibition.
• Discussion of specific examples like epidermal growth factor receptor inhibitors and imatinib mesylate.

Main Results:

• Targeting growth factor receptors is effective in treating certain cancers, such as breast cancer with anti-EGFR antibodies.
• Tyrosine kinase inhibitors, like imatinib mesylate, are successful in modulating signal transduction pathways.
• Growth factors themselves can be used to mitigate severe side effects of chemotherapy.

Conclusions:

• Growth factor signaling pathways are critical targets for cancer treatment.
• Inhibition of growth factor activity is a major therapeutic approach in oncology.
• Growth factors play a dual role, being targets for therapy and agents for supportive care.